NEW YORK, April 2, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Jazz Pharmaceuticals Plc
(NASDAQ: JAZZ), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT),
Community Health Systems, Inc. (NYSE: CYH), and United Technologies
Corporation (NYSE: UTX). Private wealth members receive these notes
ahead of publication. To reserve complementary membership, limited
openings are available at:
http://www.AnalystsReview.com/register
--
Ariad Pharmaceuticals Inc. Analyst Notes
On March 24, 2014, Ariad
Pharmaceuticals Inc. (Ariad) announced the commencement of a
pivotal global Phase II trial of AP26113 in patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) who were
previously treated with crizotinib. According to Ariad, the ALTA
(ALK in Lung Cancer Trial of AP26113) trial, designed to determine
the safety and efficacy of AP26113 in refractory NSCLC patients who
test positive for the anaplastic lymphoma kinase (ALK+) oncogene,
will have primary endpoint as objective response rate (ORR) which
is measured by RECIST criteria. Secondary endpoints include time to
response, duration of response, disease control rate,
progression-free survival, overall survival, safety, and
tolerability. The full analyst notes on Ariad Pharmaceuticals Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/04022014/ARIA/report.pdf
--
Jazz Pharmaceuticals Plc Analyst Notes
On March 28, 2014, the stock of
Jazz Pharmaceuticals Plc (Jazz) ended lower by 3.29% at
$133.46, amidst rumors in some
sections of the media that the Company is willing to pay
$20-plus a share to acquire
oncology-focused Ariad Pharmaceuticals Inc. After opening at
$136.86, the stock oscillated in the
range of $131.51 - $137.95, with a
total of 1.22 million shares changing hands. Over the past 12
months, the stock has increased by 138.71%, significantly
outperforming the Dow Jones Industrial Average which rose 11.97%
during the same period. The full analyst notes on Jazz
Pharmaceuticals Plc are available to download free of charge
at:
http://www.AnalystsReview.com/04020214/JAZZ/report.pdf
--
Intercept Pharmaceuticals Inc. Analyst Notes
On March 28, 2014, the stock of
Intercept Pharmaceuticals Inc. (Intercept) resumed its southward
journey after a brief relief and ended the session lower by 3.47%
at $317.58. The stock opened at
$326.48 and traded in the range of
$313.14 - $335.98, with a total
volume of 0.50 million shares. The stock, which quadrupled in just
one day on January 9, 2014 on
positive clinical trial results, has declined 18.76% in last five
trading sessions, which the analysts attribute to profit booking in
the overall biotechnology sector. The NASDAQ Biotechnology index
has slipped 7.02% in last five trading sessions. The full analyst
notes on Intercept Pharmaceuticals Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/04022014/ICPT/report.pdf
--
Community Health Systems, Inc. Analyst Notes
On March 19, 2014, Community
Health Systems, Inc. (CHS) announced that a subsidiary of the
Company has entered into a definitive agreement to lease 421-bed
Munroe Regional Medical Center in Ocala,
Florida, for a period of 40 years, starting Q2 2014.
According to the Company, the agreement also provides for the
creation of a clinical affiliation between Munroe Regional Medical
Center and UF Health Shands, which will hold a minority equity
position in the hospital operating company. Commenting on the
development, Wayne T. Smith,
Chairman and CEO of CHS, said, "We are very pleased to move forward
in this relationship and look forward to working with the medical
staff and employees of Munroe Regional in support of the quality
care they provide for their community. We also look forward to the
contributions UF Health Shands will bring to Munroe Regional and to
the benefits of clinical affiliation with an academic healthcare
leader in Florida." The full
analyst notes on Community Health Systems, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04022014/CYH/report.pdf
--
United Technologies Corporation Analyst Notes
On March 28, 2014, the stock of
United Technologies Corporation (UTC) closed at $114.81, up 0.89% from its previous day's close.
After opening at $114.20, the stock
oscillated in the range of $114.12 -
$115.44. During the session, a total of 2.46 million shares
were traded, which was lower than its 30-day average daily volume
of 3.38 million. The stock has gained 22.88% in last 12 months,
outperforming the Dow Jones Industrial Average which rose 11.97%
during the same period. The full analyst notes on United
Technologies Corporation are available to download free of charge
at:
http://www.AnalystsReview.com/04022014/UTX/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review